Association	O
of	O
glucocorticoid	O
insensitivity	O
with	O
increased	O
expression	O
of	O
glucocorticoid	B-protein
receptor	I-protein
beta	I-protein
.	O

In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life-threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
,	O
however	O
,	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-RNA
receptor	I-RNA
(	I-RNA
R	I-RNA
)	I-RNA
pre-messenger	I-RNA
RNA	I-RNA
generates	O
a	O
second	O
GCR	B-protein
,	O
termed	O
GCR-beta	B-protein
,	O
which	O
does	O
not	O
bind	O
GCs	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-protein
,	O
termed	O
GCR-alpha	B-protein
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrate	O
that	O
GC-insensitive	O
asthma	O
is	O
associated	O
with	O
a	O
significantly	O
higher	O
number	O
of	O
GCR-beta-immunoreactive	B-cell_type
cells	I-cell_type
in	O
peripheral	O
blood	O
than	O
GC-sensitive	O
asthmatics	O
or	O
normal	O
controls	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC-insensitive	O
asthma	O
have	O
cytokine-induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	B-protein
.	O

These	O
abnormalities	O
can	O
be	O
reproduced	O
by	O
transfection	O
of	O
cell	B-cell_line
lines	I-cell_line
with	O
the	O
GCR-beta	B-protein
gene	O
resulting	O
in	O
significant	O
reduction	O
of	O
their	O
GCR-alpha	B-protein
DNA	O
binding	O
capacity	O
.	O

We	O
conclude	O
that	O
increased	O
expression	O
of	O
GCR-beta	B-protein
is	O
cytokine	B-protein
inducible	O
and	O
may	O
account	O
for	O
GC	O
insensitivity	O
in	O
this	O
common	O
inflammatory	O
condition	O
.	O

Association	NULL
of	NULL
Glucocorticoid	NULL
Insensitivity	NULL
with	NULL
Increased	NULL
Expression	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
B	NULL
By	NULL
Donald	NULL
YM	NULL
.	NULL

Leung	NULL
,	NULL
*	NULL
Q	NULL
utayba	NULL
Hamid	NULL
,	NULL
*	NULL
Alessandra	NULL
Vottero	NULL
,	NULL
$	NULL
Stanley	NULL
J.	NULL
Szefler	NULL
,	NULL
*	NULL
Wendy	NULL
Surs	NULL
,	NULL
*	NULL
Eleanor	NULL
Minshall	NULL
,	NULL
$	NULL
George	NULL
P.	NULL
Chrousos	NULL
,	NULL
$	NULL
and	NULL
Dwight	NULL
J.	NULL
Klemm*	NULL
From	NULL
the	NULL
*Divisions	NULL
of	NULL
A	NULL
llergy-Immunology	NULL
and	NULL
Clinial	NULL
Pharmacology	NULL
,	NULL
N	NULL
ational	NULL
Jewish	NULL
Medical	NULL
and	NULL
Research	NULL
Center	NULL
and	NULL
the	NULL
*Department	NULL
of	NULL
Pediatrics	NULL
University	NULL
of	NULL
Colorudo	NULL
Health	NULL
Saences	NULL
Center	NULL
Denver	NULL
Colorado	NULL
;	NULL
the	NULL
$	NULL
Meakins-C	NULL
hristie	NULL
Laboratories	NULL
and	NULL
Departments	NULL
of	NULL
Pathology	NULL
,	NULL
MG	NULL
ill	NULL
University	NULL
,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
Canada	NULL
;	NULL
and	NULL
the	NULL
Developmental	NULL
Endocrinology	NULL
Branch	NULL
,	NULL
N	NULL
ational	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
Sum	NULL
m	NULL
ary	NULL
In	NULL
many	NULL
chronic	NULL
inflammatory	NULL
disorders	NULL
,	NULL
glucocorticoid	NULL
(	NULL
GC	NULL
)	NULL
insensitivity	NULL
is	NULL
a	NULL
challenging	NULL
clinical	NULL
problem	NULL
associated	NULL
with	NULL
life-threatening	NULL
disease	NULL
progression	NULL
.	NULL

The	NULL
molecular	NULL
basis	NULL
of	NULL
GC	NULL
in-sensitivity	NULL
,	NULL
however	NULL
,	NULL
is	NULL
unknown	NULL
.	NULL

Alternative	NULL
splicing	NULL
of	NULL
the	NULL
GC	NULL
receptor	NULL
(	NULL
R	NULL
)	NULL
pre-messenger	NULL
RNA	NULL
generates	NULL
a	NULL
second	NULL
GCR	NULL
,	NULL
termed	NULL
GCR	NULL
-B	NULL
,	NULL
which	NULL
does	NULL
not	NULL
bind	NULL
GCs	NULL
but	NULL
antagonizes	NULL
the	NULL
transactivating	NULL
activity	NULL
of	NULL
the	NULL
classic	NULL
GCR	NULL
,	NULL
termed	NULL
GCR	NULL
-	NULL
«	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
GC-	NULL
insensitive	NULL
asthma	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
significantly	NULL
higher	NULL
number	NULL
of	NULL
GCR	NULL
B-immunoreactive	NULL
cells	NULL
in	NULL
peripheral	NULL
blood	NULL
than	NULL
GC-sensitive	NULL
asthmatics	NULL
or	NULL
normal	NULL
controls	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
patients	NULL
with	NULL
GC	NULL
-	NULL
insensitive	NULL
asthma	NULL
have	NULL
cytokine-induced	NULL
abnormalities	NULL
in	NULL
the	NULL
DN	NULL
A	NULL
binding	NULL
capability	NULL
of	NULL
the	NULL
GCR	NULL
.	NULL

These	NULL
abnormalities	NULL
can	NULL
be	NULL
reproduced	NULL
by	NULL
transfection	NULL
of	NULL
cell	NULL
lines	NULL
with	NULL
the	NULL
GCR	NULL
-B	NULL
gene	NULL
resulting	NULL
in	NULL
significant	NULL
reduction	NULL
of	NULL
their	NULL
GCR	NULL
-a	NULL
DNA	NULL
binding	NULL
capacity	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
increased	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
is	NULL
cytokine	NULL
induc-	NULL
ible	NULL
and	NULL
may	NULL
account	NULL
for	NULL
GC	NULL
insensitivity	NULL
in	NULL
this	NULL
common	NULL
inflammatory	NULL
condition	NULL
.	NULL

lucocorticoid	NULL
(	NULL
GC	NULL
)	NULL
!	NULL

insensitivity	NULL
is	NULL
increasingly	NULL
being	NULL
recognized	NULL
in	NULL
the	NULL
management	NULL
of	NULL
chronic	NULL
inflammatory	NULL
diseases	NULL
such	NULL
as	NULL
asthma	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
,	NULL
and	NULL
transplantation	NULL
rejection	NULL
.	NULL

It	NULL
poses	NULL
a	NULL
major	NULL
clinical	NULL
challenge	NULL
as	NULL
GC	NULL
therapy	NULL
is	NULL
the	NULL
cornerstone	NULL
of	NULL
antiinflammatory	NULL
therapy	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
GC	NULL
insensitivity	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
development	NULL
of	NULL
new	NULL
treatment	NULL
approaches	NULL
for	NULL
this	NULL
group	NULL
of	NULL
refractory	NULL
pa-tients	NULL
,	NULL
and	NULL
may	NULL
provide	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
pathogenesis	NULL
of	NULL
chronic	NULL
inflammation	NULL
.	NULL

GC	NULL
insensitivity	NULL
has	NULL
been	NULL
most	NULL
extensively	NULL
studied	NULL
in	NULL
chronic	NULL
asthma	NULL
,	NULL
as	NULL
the	NULL
failure	NULL
here	NULL
to	NULL
respond	NULL
to	NULL
GCs	NULL
is	NULL
more	NULL
readily	NULL
demonstrated	NULL
than	NULL
in	NULL
other	NULL
inflammatory	NULL
diseases	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
on	NULL
PBMCs	NULL
from	NULL
patients	NULL
with	NULL
insensitive	NULL
asthma	NULL
have	NULL
revealed	NULL
that	NULL
GCs	NULL
fail	NULL
to	NULL
inhibit	NULL
their	NULL
mitogen-induced	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
secretion	NULL
in	NULL
vitro	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
of	NULL
GC-insensitive	NULL
asthmatics	NULL
,	NULL
but	NULL
not	NULL
GC-sensitive	NULL
asthmatics	NULL
,	NULL
are	NULL
persistently	NULL
activated	NULL
despite	NULL
high	NULL
doses	NULL
of	NULL
GC	NULL
therapy	NULL
(	NULL
4	NULL
)	NULL
.	NULL

!	NULL

A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
EMSA	NULL
,	NULL
electromobility	NULL
shift	NULL
assay	NULL
;	NULL
FEV	NULL
)	NULL
,	NULL
forced	NULL
expiratory	NULL
volume	NULL
in	NULL
one	NULL
second	NULL
;	NULL
GC	NULL
,	NULL
glucocorticoid	NULL
;	NULL
GRE	NULL
,	NULL
glu-corticoid	NULL
response	NULL
element	NULL
;	NULL
mRNA	NULL
,	NULL
messenger	NULL
RNA	NULL
.	NULL

1567	NULL
http	NULL
:	NULL
//	NULL
www.jem.org	NULL
GCs	NULL
act	NULL
by	NULL
binding	NULL
to	NULL
a	NULL
cytoplasmic	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GCR	NULL
)	NULL
which	NULL
then	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
as	NULL
a	NULL
transcription	NULL
factor	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
GC-	NULL
insensitive	NULL
asthma	NULL
have	NULL
a	NULL
revers	NULL
ible	NULL
defect	NULL
in	NULL
PBMC	NULL
GCR	NULL
ligand	NULL
binding	NULL
affinity	NULL
which	NULL
can	NULL
be	NULL
sustained	NULL
in	NULL
vitro	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
but	NULL
not	NULL
the	NULL
individual	NULL
cytokines	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
vitro	NULL
incubation	NULL
of	NULL
normal	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
reduces	NULL
their	NULL
GCR	NULL
ligand	NULL
binding	NULL
affinity	NULL
to	NULL
the	NULL
level	NULL
seen	NULL
in	NULL
GC-insensitive	NULL
asthma	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Bronchoscopy	NULL
studies	NULL
indicate	NULL
that	NULL
airway	NULL
T	NULL
cells	NULL
of	NULL
GC-insensitive	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
GC-sensitive	NULL
,	NULL
asthma	NULL
have	NULL
significantly	NULL
higher	NULL
levels	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
gene	NULL
expression	NULL
(	NULL
8	NULL
)	NULL
.	NULL

O	NULL
verall	NULL
these	NULL
data	NULL
support	NULL
the	NULL
concept	NULL
that	NULL
GC-insensitive	NULL
asthma	NULL
results	NULL
from	NULL
high	NULL
level	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
which	NULL
leads	NULL
to	NULL
reduced	NULL
GCR	NULL
binding	NULL
affinity	NULL
and	NULL
decreased	NULL
T	NULL
cell	NULL
responsiveness	NULL
to	NULL
GCs	NULL
.	NULL

Independent	NULL
studies	NULL
by	NULL
other	NULL
investigators	NULL
have	NULL
recently	NULL
reported	NULL
that	NULL
PBMCs	NULL
from	NULL
patients	NULL
with	NULL
GC-insensitive	NULL
asthma	NULL
have	NULL
a	NULL
decreased	NULL
ability	NULL
of	NULL
their	NULL
GCR	NULL
s	NULL
to	NULL
bind	NULL
its	NULL
specific	NULL
DN	NULL
A	NULL
recognition	NULL
sequence	NULL
(	NULL
glucocorticoid	NULL
response	NULL
elements	NULL
,	NULL
ie	NULL
.	NULL

,	NULL
GRE	NULL
;	NULL
reference	NULL
9	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
extended	NULL
our	NULL
analysis	NULL
of	NULL
PBMCs	NULL
from	NULL
GC	NULL
-	NULL
insensitive	NULL
asthmatics	NULL
to	NULL
demonstrate	NULL
that	NULL
our	NULL
patients	NULL
previously	NULL
found	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Experimental	NULL
Medicine	NULL
«	NULL
Volume	NULL
186	NULL
,	NULL
Number	NULL
9	NULL
,	NULL
November	NULL
3	NULL
,	NULL
1997	NULL
1567-1574	NULL
have	NULL
abnormally	NULL
low	NULL
GCR	NULL
ligand	NULL
binding	NULL
affinity	NULL
also	NULL
have	NULL
a	NULL
GCR	NULL
DNA	NULL
binding	NULL
defect	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
we	NULL
report	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
the	NULL
combined	NULL
GCR	NULL
ligand	NULL
and	NULL
DNA	NULL
binding	NULL
defect	NULL
in	NULL
GC-insensitive	NULL
asthma	NULL
is	NULL
due	NULL
to	NULL
cytokine-induced	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
,	NULL
a	NULL
newly	NULL
identified	NULL
inhibitor	NULL
of	NULL
GC	NULL
action	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Patient	NULL
Selection	NULL
.	NULL

Informed	NULL
consent	NULL
was	NULL
obtained	NULL
from	NULL
all	NULL
patients	NULL
before	NULL
their	NULL
entry	NULL
into	NULL
this	NULL
study	NULL
.	NULL

Patients	NULL
with	NULL
a	NULL
diagnosis	NULL
of	NULL
asthma	NULL
,	NULL
based	NULL
on	NULL
The	NULL
American	NULL
Thoracic	NULL
Society	NULL
criteria	NULL
(	NULL
10	NULL
)	NULL
,	NULL
were	NULL
selected	NULL
for	NULL
evaluation	NULL
.	NULL

They	NULL
were	NULL
included	NULL
if	NULL
they	NULL
had	NULL
a	NULL
morning	NULL
prebronchodilator	NULL
FEV	NULL
,	NULL
<	NULL
70	NULL
%	NULL
of	NULL
predicted	NULL
values	NULL
and	NULL
a	NULL
>	NULL
15	NULL
%	NULL
increase	NULL
in	NULL
forced	NULL
expiratory	NULL
volume	NULL
in	NULL
one	NULL
second	NULL
(	NULL
FEV	NULL
)	NULL
after	NULL
two	NULL
inhalations	NULL
of	NULL
albuterol	NULL
(	NULL
90	NULL
g/	NULL
actuation	NULL
)	NULL
.	NULL

Patients	NULL
were	NULL
excluded	NULL
if	NULL
they	NULL
had	NULL
evidence	NULL
for	NULL
other	NULL
types	NULL
of	NULL
lung	NULL
disease	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
as	NULL
GC-sensitive	NULL
or	NULL
GC-insensitive	NULL
based	NULL
on	NULL
their	NULL
prebronchodilator	NULL
morning	NULL
FEV	NULL
;	NULL
and	NULL
response	NULL
to	NULL
a	NULL
course	NULL
of	NULL
oral	NULL
prednisone	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Asthmatic	NULL
patients	NULL
were	NULL
defined	NULL
as	NULL
GC-insensitive	NULL
if	NULL
they	NULL
failed	NULL
to	NULL
improve	NULL
their	NULL
morning	NULL
prebronchodilator	NULL
FEV	NULL
,	NULL
by	NULL
>	NULL
15	NULL
%	NULL
after	NULL
a	NULL
1-wk	NULL
course	NULL
of	NULL
prednisone	NULL
at	NULL
a	NULL
minimum	NULL
oral	NULL
dose	NULL
of	NULL
40	NULL
mg/	NULL
day	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
as	NULL
GC-sensitive	NULL
if	NULL
they	NULL
had	NULL
an	NULL
increase	NULL
in	NULL
baseline	NULL
FEV	NULL
,	NULL
of	NULL
30	NULL
%	NULL
or	NULL
greater	NULL
.	NULL

Cell	NULL
Cultures	NULL
.	NULL

Peripheral	NULL
blood	NULL
was	NULL
collected	NULL
in	NULL
heparinized	NULL
syringes	NULL
and	NULL
PBMCs	NULL
isolated	NULL
by	NULL
Ficoll-Paque®	NULL
(	NULL
Pharmacia	NULL
,	NULL
Pis	NULL
cataway	NULL
,	NULL
NJ	NULL
)	NULL
gradient	NULL
centrifugation	NULL
.	NULL

PBMCs	NULL
from	NULL
normal	NULL
donors	NULL
and	NULL
insensitive	NULL
asthma	NULL
patients	NULL
were	NULL
isolated	NULL
and	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10°	NULL
cells/	NULL
ml	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Hy-Clone	NULL
Labs	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
IL-2	NULL
(	NULL
50	NULL
U/ml	NULL
;	NULL
Chiron	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
and/or	NULL
IL-4	NULL
(	NULL
50	NULL
U/ml	NULL
;	NULL
Schering-Plough	NULL
Research	NULL
Institute	NULL
,	NULL
Bloomfield	NULL
,	NULL
NJ	NULL
)	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
before	NULL
analysis	NULL
.	NULL

Eledrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
.	NULL

-	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
PBMCs	NULL
as	NULL
previously	NULL
described	NULL
in	NULL
reference	NULL
11	NULL
.	NULL

GCR	NULL
DNA	NULL
binding	NULL
was	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
using	NULL
a	NULL
30-bp	NULL
double-stranded	NULL
oligonucleotide	NULL
composed	NULL
of	NULL
two	NULL
complementary	NULL
strands	NULL
:	NULL
5-TCGACTGATTA-CAAACTGTTCTTGCTACT-3	NULL
'	NULL
and	NULL
S5'-AGTAGCAAGAA-CAGTTTGTAATCAGTCGA-3	NULL
'	NULL
.	NULL

The	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
P-	NULL
ATP	NULL
and	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

The	NULL
labeled	NULL
probe	NULL
(	NULL
50,000	NULL
epm/	NULL
reaction	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
PBMC	NULL
nuclear	NULL
extract	NULL
protein	NULL
(	NULL
~5	NULL
jg	NULL
)	NULL
in	NULL
20-pul	NULL
reactions	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
7.9	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
3	NULL
mM	NULL
MgC1	NULL
;	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
1	NULL
jg	NULL
poly	NULL
dl	NULL
:	NULL
dC	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Some	NULL
reactions	NULL
also	NULL
contained	NULL
other	NULL
oligonucleotides	NULL
and	NULL
antibodies	NULL
to	NULL
c-Jun	NULL
or	NULL
NF-KB	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
as	NULL
indicated	NULL
for	NULL
specificity	NULL
controls	NULL
.	NULL

Affinity-purified	NULL
rabbit	NULL
anti-human	NULL
GCR	NULL
(	NULL
Affinity	NULL
BioR	NULL
eagents	NULL
,	NULL
Neshanic	NULL
Station	NULL
,	NULL
NJ	NULL
)	NULL
was	NULL
also	NULL
used	NULL
for	NULL
supershift	NULL
experiments	NULL
.	NULL

Reactions	NULL
were	NULL
then	NULL
separated	NULL
on	NULL
6	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
containing	NULL
0.25	NULL
%	NULL
tris-	NULL
buric	NULL
acid	NULL
EDT	NULL
A	NULL
buffer	NULL
at	NULL
250	NULL
V	NULL
until	NULL
the	NULL
free	NULL
oligonucleotide	NULL
probe	NULL
had	NULL
migrated	NULL
to	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

Gels	NULL
were	NULL
then	NULL
exposed	NULL
to	NULL
Kodak	NULL
XAR5	NULL
film	NULL
(	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
GCR	NULL
DNA	NULL
binding	NULL
was	NULL
quantitated	NULL
by	NULL
densitometry	NULL
of	NULL
the	NULL
developed	NULL
films	NULL
.	NULL

Saturation	NULL
binding	NULL
assays	NULL
for	NULL
GCR	NULL
DNA	NULL
binding	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
reactions	NULL
contained	NULL
~5	NULL
jpg	NULL
of	NULL
PBMC	NULL
nuclear	NULL
extract	NULL
protein	NULL
and	NULL
from	NULL
0.1	NULL
to	NULL
100	NULL
ng	NULL
of	NULL
labeled	NULL
glutocorticoid	NULL
response	NULL
element	NULL
(	NULL
GRE	NULL
)	NULL
probe	NULL
.	NULL

After	NULL
the	NULL
reactions	NULL
were	NULL
resolved	NULL
on	NULL
polyacrylamide	NULL
gels	NULL
,	NULL
levels	NULL
of	NULL
bound	NULL
and	NULL
free	NULL
1568	NULL
probe	NULL
in	NULL
each	NULL
reaction	NULL
were	NULL
determined	NULL
by	NULL
densitometry	NULL
of	NULL
auto-radiograms	NULL
.	NULL

Dissociation	NULL
constants	NULL
(	NULL
Kds	NULL
)	NULL
for	NULL
GCR	NULL
DNA	NULL
binding	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
slope	NULL
of	NULL
curves	NULL
of	NULL
saturation	NULL
binding	NULL
data	NULL
plotted	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Westem	NULL
Blot	NULL
Analysis	NULL
of	NULL
GCR	NULL
.	NULL

PBMC	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
.	NULL

After	NULL
correcting	NULL
for	NULL
protein	NULL
concen-trations	NULL
,	NULL
~50	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
was	NULL
resolved	NULL
on	NULL
10	NULL
%	NULL
polyacrylamide-SDS	NULL
gels	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
.	NULL

The	NULL
nitrocellulose	NULL
blots	NULL
were	NULL
blocked	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
5	NULL
%	NULL
dry	NULL
milk	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
affinity-purified	NULL
rabbit	NULL
anti-human	NULL
GCR	NULL
(	NULL
Affinity	NULL
Bio	NULL
Re-agents	NULL
,	NULL
Neshanic	NULL
Station	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
washed	NULL
and	NULL
subsequently	NULL
treated	NULL
with	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
conjugated	NULL
to	NULL
alkaline	NULL
phosphatase	NULL
.	NULL

After	NULL
the	NULL
blots	NULL
were	NULL
washed	NULL
,	NULL
specific	NULL
immune	NULL
complexes	NULL
were	NULL
visualized	NULL
with	NULL
bromo-chloro-indoyl-phosphate	NULL
and	NULL
nitroblue	NULL
tetrazolium	NULL
.	NULL

Immunchistochemistry	NULL
Staining	NULL
.	NULL

_	NULL
GCR	NULL
-B	NULL
immunoreactivity	NULL
was	NULL
detected	NULL
in	NULL
acetone/	NULL
methanol-fixed	NULL
cytospins	NULL
of	NULL
PBMCs	NULL
by	NULL
the	NULL
use	NULL
of	NULL
a	NULL
GCR	NULL
-	NULL
B-specific	NULL
polyclonal	NULL
rabbit	NULL
antibody	NULL
raised	NULL
against	NULL
human	NULL
GCR	NULL
-B	NULL
.	NULL

This	NULL
antibody	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
GCR-B	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
has	NULL
no	NULL
cross-reactivity	NULL
against	NULL
GCR	NULL
-a	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
antibody-antigen	NULL
reaction	NULL
for	NULL
im-munocytochemistry	NULL
was	NULL
tested	NULL
by	NULL
preabsorption	NULL
of	NULL
the	NULL
antibody	NULL
with	NULL
excess	NULL
purified	NULL
GCR	NULL
-B	NULL
antigen	NULL
which	NULL
resulted	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
reactivity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
visualized	NULL
using	NULL
the	NULL
avidin-biotin-peroxidase	NULL
complex	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

For	NULL
negative	NULL
control	NULL
preparations	NULL
,	NULL
the	NULL
primary	NULL
antibody	NULL
was	NULL
replaced	NULL
by	NULL
either	NULL
nonspecific	NULL
rabbit	NULL
immunoglobulin	NULL
or	NULL
Tris	NULL
buffered	NULL
saline	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
positive	NULL
for	NULL
GCR	NULL
-B	NULL
in	NULL
each	NULL
preparation	NULL
were	NULL
enumerated	NULL
by	NULL
a	NULL
blinded	NULL
assessor	NULL
counting	NULL
a	NULL
minimum	NULL
of	NULL
1,000	NULL
total	NULL
cells	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

-	NULL
Group	NULL
means	NULL
were	NULL
expressed	NULL
as	NULL
the	NULL
arithmetic	NULL
mean	NULL
+	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
.	NULL

Statistical	NULL
comparisons	NULL
between	NULL
groups	NULL
used	NULL
the	NULL
Student	NULL
's	NULL
f	NULL
test	NULL
(	NULL
nonpaired	NULL
)	NULL
with	NULL
the	NULL
P	NULL
<	NULL
0.05	NULL
representing	NULL
a	NULL
significant	NULL
result	NULL
.	NULL

o	NULL
23	NULL
g	NULL
O	NULL
I	NULL
a.	NULL
O	NULL
co	NULL
L	NULL
U	NULL
it	NULL
8	NULL
&	NULL
a	NULL
O	NULL
0	NULL
G	NULL
p	NULL
<	NULL
#	NULL
g	NULL
w	NULL
y	NULL
,	NULL
5	NULL
8	NULL
Addition	NULL
:	NULL
§	NULL
§	NULL
§	NULL
§	NULL
4	NULL
&	NULL
5	NULL
'*zz	NULL
f	NULL
2	NULL
62	NULL
G	NULL
Dexamethasone	NULL
:	NULL
-	NULL
+	NULL
+	NULL
+	NULL
++	NULL
+	NULL
-F	NULL
Dimer	NULL
c	NULL
~~	NULL
``	NULL
_	NULL
w	NULL
_	NULL
__4	NULL
KX	NULL
.	NULL

C.	NULL
-	NULL
Monomer	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Specificity	NULL
of	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
blot	NULL
for	NULL
GCR-GRE	NULL
interactions	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
a	NULL
normal	NULL
subject	NULL
.	NULL

The	NULL
specific	NULL
monomeric	NULL
and	NULL
dimeric	NULL
GCR-GRE	NULL
retarded	NULL
bands	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
dexamethasone	NULL
(	NULL
1	NULL
M	NULL
)	NULL
on	NULL
the	NULL
density	NULL
of	NULL
the	NULL
GCR-GRE	NULL
band	NULL
is	NULL
shown	NULL
at	NULL
60	NULL
min	NULL
.	NULL

Specificity	NULL
is	NULL
shown	NULL
by	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
and	NULL
anti-GCR	NULL
antibody	NULL
on	NULL
GCR-GRE	NULL
binding	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
B	NULL
in	NULL
Glucorticoid-insensitive	NULL
Asthma	NULL
Figure	NULL
2	NULL
.	NULL

GCR	NULL
binding	NULL
to	NULL
specific	NULL
_	NULL
consensus	NULL
_	NULL
double-stranded	NULL
DNA	NULL
-	NULL
binding	NULL
-	NULL
se	NULL
Glucocorticoid	NULL
Sensitive	NULL
``	NULL
°	NULL
Glucocorticoid	NULL
Insensitive	NULL
Fl	NULL
E	NULL
5	NULL
C	NULL
-	NULL
iso	NULL
A	NULL
102	NULL
s	NULL
|f	NULL
2	NULL
s	NULL
fA	NULL
3	NULL
4	NULL
2	NULL
$	NULL
6	NULL
100	NULL
--	NULL
.	NULL

(	NULL
D	NULL
&	NULL
<	NULL
l	NULL
ss	NULL
hf	NULL
ig	NULL
20	NULL
so	NULL
RER	NULL
___|	NULL
o.	NULL
cue	NULL
.	NULL

--	NULL
on	NULL
comme	NULL
mmm	NULL
mae	NULL
me	NULL
mikes	NULL
quences	NULL
for	NULL
GRE	NULL
in	NULL
nuclear	NULL
extracts	NULL
obtained	NULL
from	NULL
PBMCs	NULL
from	NULL
GC-insensitive	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
,	NULL
GC	NULL
-sensitive	NULL
asthmatics	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
subjects	NULL
(	NULL
r	NULL
=	NULL
10	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
representative	NULL
EMSA	NULL
for	NULL
GCR-GRE	NULL
interactions	NULL
using	NULL
freshly	NULL
isolated	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBMCs	NULL
of	NULL
three	NULL
normal	NULL
1	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
8	NULL
g	NULL
10/1	NULL
Normal	NULL
subjects	NULL
,	NULL
three	NULL
-	NULL
GC-sensitive	NULL
,	NULL
and	NULL
four	NULL
GC-insensitive	NULL
asth-	NULL
H	NULL
matics	NULL
.	NULL

(	NULL
B	NULL
)	NULL
A	NULL
Western	NULL
blot	NULL
of	NULL
the	NULL
LLL	NULL
.	NULL

IL	NULL
IITIITIDI	NULL
{	NULL
44	NULL
same	NULL
PBMC	NULL
nuclear	NULL
extracts	NULL
2	NULL
a	NULL
4	NULL
5	NULL
6/1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
probed	NULL
-	NULL
with	NULL
-	NULL
affinity-purified	NULL
Glucocorticoid	NULL
Glucacerticoid	NULL
rabbit	NULL
anti-human	NULL
GCR	NULL
(	NULL
Affin-Sensitive	NULL
Insensitive	NULL
ity	NULL
BioReagents	NULL
,	NULL
Neshanic	NULL
Station	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
nu	NULL
clear	NULL
extract	NULL
protein	NULL
were	NULL
assayed	NULL
in	NULL
each	NULL
lane	NULL
of	NULL
A	NULL
and	NULL
B	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
average	NULL
,	NULL
relative	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBMCs	NULL
of	NULL
normal	NULL
,	NULL
GC	NULL
-sensitive	NULL
,	NULL
and	NULL
GC-insensitive	NULL
subjects	NULL
determined	NULL
by	NULL
densitometric	NULL
quantitation	NULL
of	NULL
multiple	NULL
experiments	NULL
.	NULL

Levels	NULL
are	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
maximum	NULL
binding	NULL
observed	NULL
in	NULL
normal	NULL
subjects	NULL
.	NULL

Results	NULL
An	NULL
EMSA	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
the	NULL
interaction	NULL
between	NULL
GCR	NULL
and	NULL
its	NULL
specific	NULL
DNA	NULL
recognition	NULL
sequence	NULL
or	NULL
GRE	NULL
.	NULL

The	NULL
first	NULL
step	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
to	NULL
confirm	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
observed	NULL
in	NULL
our	NULL
EMSAs	NULL
was	NULL
due	NULL
to	NULL
GCR	NULL
DNA	NULL
binding	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
two	NULL
retarded	NULL
bands	NULL
,	NULL
corresponding	NULL
to	NULL
monomeric	NULL
and	NULL
dimeric	NULL
GCR	NULL
s	NULL
,	NULL
were	NULL
observed	NULL
in	NULL
EMSAs	NULL
performed	NULL
with	NULL
a	NULL
30-bp	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
consensus	NULL
GRE	NULL
.	NULL

Although	NULL
these	NULL
two	NULL
bands	NULL
were	NULL
observed	NULL
in	NULL
reactions	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
untreated	NULL
cells	NULL
,	NULL
their	NULL
intensity	NULL
was	NULL
much	NULL
higher	NULL
in	NULL
reactions	NULL
containing	NULL
extracts	NULL
from	NULL
dexamethasone-treated	NULL
cells	NULL
.	NULL

A	NULL
100-fold	NULL
excess	NULL
of	NULL
cold	NULL
nonspecific	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
consensus	NULL
CCAAT/enhancer	NULL
binding	NULL
protein	NULL
binding	NULL
sequence	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
DN	NULL
A	NULL
binding	NULL
activity	NULL
,	NULL
but	NULL
excess	NULL
cold	NULL
GRE	NULL
oligonucleotide	NULL
completely	NULL
inhibited	NULL
formation	NULL
of	NULL
the	NULL
two	NULL
retarded	NULL
bands	NULL
.	NULL

Likewise	NULL
,	NULL
antibodies	NULL
to	NULL
the	NULL
GCR	NULL
completely	NULL
blocked	NULL
complex	NULL
formation	NULL
,	NULL
whereas	NULL
antibodies	NULL
to	NULL
other	NULL
transcription	NULL
factors	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
dexamethasone	NULL
to	NULL
enhance	NULL
complex	NULL
formation	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
GCR	NULL
specific	NULL
antibodies	NULL
and	NULL
oligonucleotides	NULL
to	NULL
inhibit	NULL
their	NULL
formation	NULL
clearly	NULL
indicates	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
observed	NULL
in	NULL
these	NULL
reactions	NULL
is	NULL
due	NULL
to	NULL
the	NULL
GCR	NULL
.	NULL

We	NULL
next	NULL
compared	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
10	NULL
normal	NULL
subjects	NULL
,	NULL
6	NULL
GC-sensitive	NULL
,	NULL
and	NULL
8	NULL
GC-insensitive	NULL
individuals	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
dexamethasone	NULL
to	NULL
translocate	NULL
the	NULL
GCR	NULL
s	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

We	NULL
found	NULL
significant	NULL
levels	NULL
of	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
normal	NULL
and	NULL
GC-sensitive	NULL
individuals	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
)	NULL
.	NULL

When	NULL
quantitated	NULL
by	NULL
densitometry	NULL
of	NULL
the	NULL
autoradiographs	NULL
,	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
GCR	NULL
DNA	NULL
binding	NULL
levels	NULL
was	NULL
noted	NULL
between	NULL
these	NULL
two	NULL
populations	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
GC-insensitive	NULL
patients	NULL
demonstrated	NULL
significantly	NULL
lower	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
levels	NULL
of	NULL
GCR	NULL
DNA	NULL
binding	NULL
than	NULL
normals	NULL
or	NULL
GC	NULL
-sensitive	NULL
individuals	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
decreased	NULL
binding	NULL
in	NULL
these	NULL
sam	NULL
1569	NULL
_	NULL
Leung	NULL
et	NULL
al	NULL
.	NULL

ples	NULL
was	NULL
not	NULL
due	NULL
to	NULL
decreased	NULL
GCR	NULL
protein	NULL
levels	NULL
,	NULL
as	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
normal	NULL
,	NULL
GC	NULL
-sensitive	NULL
,	NULL
and	NULL
GC-	NULL
insensitive	NULL
subjects	NULL
revealed	NULL
comparable	NULL
levels	NULL
of	NULL
GCR	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
)	NULL
.	NULL

The	NULL
low	NULL
levels	NULL
of	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
the	NULL
GC-insensitive	NULL
samples	NULL
appears	NULL
to	NULL
be	NULL
due	NULL
to	NULL
decreased	NULL
GCR	NULL
DNA	NULL
binding	NULL
affinity	NULL
as	NULL
compared	NULL
to	NULL
binding	NULL
in	NULL
normal	NULL
and	NULL
GC-sensitive	NULL
individuals	NULL
determined	NULL
by	NULL
saturation	NULL
binding	NULL
experiments	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
shows	NULL
a	NULL
Scatchard	NULL
plot	NULL
of	NULL
a	NULL
representative	NULL
saturation	NULL
binding	NULL
experiment	NULL
comparing	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
a	NULL
GC-sensitive	NULL
subject	NULL
to	NULL
binding	NULL
in	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
a	NULL
GC-sensitive	NULL
patient	NULL
.	NULL

The	NULL
slope	NULL
of	NULL
the	NULL
curve	NULL
derived	NULL
from	NULL
the	NULL
GC-sensitive	NULL
patient	NULL
indicates	NULL
a	NULL
K	NULL
,	NULL
of	NULL
~10-°	NULL
M	NULL
,	NULL
whereas	NULL
the	NULL
curve	NULL
obtained	NULL
from	NULL
the	NULL
GC-insensitive	NULL
patient	NULL
indicated	NULL
a	NULL
lower	NULL
affinity	NULL
interaction	NULL
with	NULL
a	NULL
K	NULL
,	NULL
of	NULL
10-8	NULL
M.	NULL
We	NULL
next	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
on	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
GC-insensitive	NULL
individuals	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
Figure	NULL
3	NULL
.	NULL

Saturation	NULL
binding	NULL
analysis	NULL
of	NULL
GCR	NULL
DNA	NULL
binding	NULL
affinity	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
GC	NULL
-sensitive	NULL
and	NULL
GC-insensitive	NULL
patients	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
PBMCs	NULL
of	NULL
a	NULL
GC-sensitive	NULL
and	NULL
a	NULL
GC-insensitive	NULL
asthmatic	NULL
.	NULL

Approximately	NULL
5	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
from	NULL
each	NULL
subject	NULL
was	NULL
incubated	NULL
in	NULL
reactions	NULL
with	NULL
concentrations	NULL
of	NULL
P-labeled	NULL
GRE	NULL
probe	NULL
from	NULL
0.1	NULL
to	NULL
100	NULL
ng	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
separated	NULL
on	NULL
polyacrylamide	NULL
gels	NULL
and	NULL
exposed	NULL
to	NULL
film	NULL
.	NULL

The	NULL
resulting	NULL
autoradiograms	NULL
were	NULL
subjected	NULL
to	NULL
densitometry	NULL
to	NULL
quantitate	NULL
levels	NULL
of	NULL
bound	NULL
and	NULL
free	NULL
probe	NULL
.	NULL

Both	NULL
shifted	NULL
bands	NULL
were	NULL
included	NULL
in	NULL
the	NULL
bound	NULL
probe	NULL
levels	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
the	NULL
binding	NULL
data	NULL
plotted	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
.	NULL

Bound/Free	NULL
Glucocorticoid	NULL
A	NULL
Insensitive	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Time	NULL
,	NULL
hrs	NULL
:	NULL
0	NULL
48	NULL
48	NULL
]	NULL
0	NULL
48	NULL
48	NULL
]	NULL
0	NULL
48	NULL
48	NULL
]	NULL
0	NULL
48	NULL
48	NULL
IL2	NULL
+	NULL
IL4	NULL
:	NULL
-	NULL
-	NULL
4+	NULL
]	NULL
-	NULL
-	NULL
4+	NULL
]	NULL
-	NULL
=	NULL
+|=-	NULL
-	NULL
+	NULL
100	NULL
Percent	NULL
Relative	NULL
GCR	NULL
DNA	NULL
Binding	NULL
on	NULL
~	NULL
T_T	NULL
ro	NULL
T.	NULL
[	NULL
th	NULL
Figure	NULL
4	NULL
.	NULL

-	NULL
Reversibility	NULL
and	NULL
cytokine	NULL
induction	NULL
of	NULL
GCR	NULL
DNA	NULL
binding	NULL
abnormalities	NULL
in	NULL
GC-insensitive	NULL
asthmatics	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
freshly	NULL
isolated	NULL
PBMCs	NULL
or	NULL
after	NULL
incubation	NULL
with	NULL
culture	NULL
medium	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
(	NULL
50	NULL
U/	NULL
ml	NULL
)	NULL
and	NULL
IL-4	NULL
(	NULL
50	NULL
U/ml	NULL
)	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

GCR	NULL
DNA	NULL
binding	NULL
was	NULL
then	NULL
analyzed	NULL
by	NULL
EMSA	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
section	NULL
.	NULL

were	NULL
prepared	NULL
from	NULL
freshly	NULL
isolated	NULL
PBMCs	NULL
or	NULL
from	NULL
cells	NULL
incubated	NULL
in	NULL
culture	NULL
for	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
four	NULL
experiments	NULL
using	NULL
PBMCs	NULL
from	NULL
four	NULL
GC-insensitive	NULL
patients	NULL
As	NULL
ex-pected	NULL
,	NULL
very	NULL
little	NULL
GCR	NULL
DNA	NULL
binding	NULL
was	NULL
present	NULL
in	NULL
freshly	NULL
isolated	NULL
PBMCs	NULL
from	NULL
any	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

However	NULL
,	NULL
after	NULL
48	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
,	NULL
there	NULL
was	NULL
a	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
increase	NULL
in	NULL
GCR	NULL
DNA	NULL
binding	NULL
in	NULL
all	NULL
four	NULL
samples	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
increase	NULL
in	NULL
GCR	NULL
DNA	NULL
binding	NULL
was	NULL
blocked	NULL
or	NULL
inhibited	NULL
in	NULL
the	NULL
cells	NULL
cultured	NULL
in	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
these	NULL
two	NULL
cytokines	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
triggering	NULL
and	NULL
maintaining	NULL
the	NULL
GCR	NULL
DN	NULL
A	NULL
binding	NULL
defect	NULL
.	NULL

The	NULL
actual	NULL
mechanisms	NULL
by	NULL
which	NULL
cytokines	NULL
or	NULL
immune	NULL
activation	NULL
might	NULL
induce	NULL
a	NULL
decrease	NULL
in	NULL
GCR	NULL
binding	NULL
are	NULL
unknown	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
human	NULL
GCR	NULL
cDNA	NULL
and	NULL
gene	NULL
revealed	NULL
that	NULL
alternative	NULL
splicing	NULL
of	NULL
the	NULL
GCR	NULL
pre-messenger	NULL
RNA	NULL
(	NULL
mRNA	NULL
)	NULL
gives	NULL
rise	NULL
to	NULL
an	NULL
additional	NULL
homologous	NULL
mRNA	NULL
and	NULL
protein	NULL
isoform	NULL
,	NULL
termed	NULL
GCR	NULL
-B	NULL
,	NULL
that	NULL
is	NULL
dis	NULL
tinct	NULL
from	NULL
the	NULL
ligand-activated	NULL
classical	NULL
GCR	NULL
,	NULL
GCR	NULL
-a	NULL
.	NULL

Both	NULL
mR	NULL
N	NULL
As	NULL
contain	NULL
the	NULL
first	NULL
eight	NULL
exons	NULL
of	NULL
the	NULL
GCR	NULL
gene	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
remainder	NULL
is	NULL
derived	NULL
by	NULL
alternative	NULL
splicing	NULL
of	NULL
the	NULL
nu	NULL
ug	NULL
pUC-19	NULL
504945	NULL
40	NULL
0	NULL
ug	NULL
pHook-1	NULL
5	NULL
5	NULL
5	NULL
5	NULL
5	NULL
ug	NULL
pRSv-GRpB	NULL
0	NULL
1	NULL
5	NULL
1050	NULL
Figure	NULL
5	NULL
.	NULL

Overexpression	NULL
of	NULL
GCR-B	NULL
reduces	NULL
GCR	NULL
DNA	NULL
binding	NULL
affinity	NULL
.	NULL

HepG2	NULL
cells	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagles	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
cotransfected	NULL
with	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
the	NULL
GCR	NULL
-B	NULL
expression	NULL
plasmid	NULL
,	NULL
wat	NULL
pRSV-GCR-B	NULL
,	NULL
and	NULL
5	NULL
pg	NULL
w	NULL
pHook-1	NULL
plasmid	NULL
by	NULL
CaPO/	NULL
DNA	NULL
coprecipitation	NULL
.	NULL

Carrier	NULL
DNA	NULL
(	NULL
pUC19	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
precipitation	NULL
reactions	NULL
to	NULL
bring	NULL
them	NULL
to	NULL
60	NULL
jpg	NULL
total	NULL
DNA	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
separated	NULL
from	NULL
untransfected	NULL
cells	NULL
us	NULL
ing	NULL
the	NULL
Capture-Tec	NULL
System	NULL
(	NULL
Invitrogen	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
directions	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
cells	NULL
and	NULL
equal	NULL
amounts	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
(	NULL
5	NULL
pg	NULL
each	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
with	NULL
labeled	NULL
GRE	NULL
probe	NULL
as	NULL
described	NULL
above	NULL
.	NULL

cleotide	NULL
sequence	NULL
encoded	NULL
by	NULL
the	NULL
last	NULL
exon	NULL
of	NULL
the	NULL
GCR	NULL
gene	NULL
,	NULL
corresponding	NULL
to	NULL
either	NULL
exon	NULL
9a	NULL
or	NULL
9B	NULL
.	NULL

The	NULL
two	NULL
protein	NULL
isoforms	NULL
have	NULL
the	NULL
same	NULL
first	NULL
727	NULL
NH	NULL
,	NULL
-terminal	NULL
amino	NULL
acids	NULL
GCR-B	NULL
differs	NULL
from	NULL
GCR-a	NULL
«	NULL
only	NULL
in	NULL
its	NULL
COOH	NULL
terminus	NULL
with	NULL
replacement	NULL
of	NULL
the	NULL
last	NULL
50	NULL
amino	NULL
acids	NULL
of	NULL
GCR	NULL
-a	NULL
with	NULL
a	NULL
unique	NULL
15	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

These	NULL
differences	NULL
render	NULL
GCR	NULL
-B	NULL
unable	NULL
to	NULL
bind	NULL
GC	NULL
hor-mones	NULL
,	NULL
thereby	NULL
antagonizing	NULL
the	NULL
transactivating	NULL
activity	NULL
of	NULL
the	NULL
classic	NULL
GCR	NULL
-a	NULL
molecule	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
also	NULL
indicate	NULL
that	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
GC	NULL
,	NULL
GCR	NULL
-B	NULL
heterodimer-izes	NULL
with	NULL
ligand-bound	NULL
GCR	NULL
-a	NULL
and	NULL
translocates	NULL
into	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
acts	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
inhibitor	NULL
of	NULL
the	NULL
classic	NULL
GCR	NULL
(	NULL
13	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
overexpression	NULL
of	NULL
GCR	NULL
-B	NULL
might	NULL
also	NULL
result	NULL
in	NULL
reduced	NULL
GCR	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
HepG2	NULL
cell	NULL
lines	NULL
were	NULL
transfected	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
a	NULL
plasmid	NULL
,	NULL
pR	NULL
SV-GCR	NULL
-	NULL
,	NULL
from	NULL
which	NULL
the	NULL
full-length	NULL
GCR	NULL
-B	NULL
protein	NULL
was	NULL
expressed	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
plasmid	NULL
,	NULL
pHook-1	NULL
,	NULL
which	NULL
allowed	NULL
us	NULL
to	NULL
separate	NULL
the	NULL
transfected	NULL
cells	NULL
from	NULL
untransfected	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
Capture-Tec	NULL
System	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
transfected	NULL
,	NULL
GCR	NULL
-B-expressing	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
EMSA	NULL
using	NULL
the	NULL
labeled	NULL
GRE	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
the	NULL
introduction	NULL
of	NULL
GCR	NULL
-B	NULL
into	NULL
HepG2	NULL
cells	NULL
inhibits	NULL
GCR	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
GCR	NULL
-B	NULL
to	NULL
block	NULL
GCR	NULL
DNA	NULL
binding	NULL
exhibited	NULL
concentration	NULL
dependence	NULL
as	NULL
very	NULL
little	NULL
inhibition	NULL
of	NULL
binding	NULL
was	NULL
noted	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
1	NULL
or	NULL
5	NULL
ug	NULL
of	NULL
pRSV-GCR	NULL
-B	NULL
.	NULL

However	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
GCR	NULL
-B	NULL
plasmid	NULL
decreased	NULL
GCR	NULL
DNA	NULL
binding	NULL
by	NULL
~25	NULL
%	NULL
,	NULL
and	NULL
50	NULL
g	NULL
of	NULL
plasmid	NULL
blocked	NULL
binding	NULL
by	NULL
70	NULL
%	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
overexpression	NULL
of	NULL
GCR	NULL
-B	NULL
in	NULL
HepG2	NULL
cells	NULL
inhibited	NULL
GCR	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Figure	NULL
6	NULL
.	NULL

Immunohistochemistry	NULL
staining	NULL
of	NULL
PBMCs	NULL
for	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
.	NULL

Low	NULL
power	NULL
magnification	NULL
(	NULL
X	NULL
100	NULL
)	NULL
of	NULL
cytospin	NULL
preparations	NULL
from	NULL
PB	NULL
MCs	NULL
from	NULL
(	NULL
a	NULL
)	NULL
GC-insensitive	NULL
and	NULL
(	NULL
b	NULL
)	NULL
GC	NULL
-sensitive	NULL
patients	NULL
immunostained	NULL
for	NULL
GCR	NULL
-B	NULL
.	NULL

Note	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
GCR	NULL
-	NULL
B-immunoreactive	NULL
cells	NULL
in	NULL
the	NULL
insensitive	NULL
compared	NULL
to	NULL
GC	NULL
-sensitive	NULL
asthmatics	NULL
.	NULL

High	NULL
power	NULL
magnification	NULL
(	NULL
X400	NULL
)	NULL
of	NULL
GCR	NULL
-	NULL
immunoreactivity	NULL
in	NULL
PBMCs	NULL
of	NULL
(	NULL
d	NULL
GC-insensitive	NULL
and	NULL
(	NULL
d	NULL
)	NULL
GC	NULL
-sensitive	NULL
patients	NULL
.	NULL

Representative	NULL
examples	NULL
of	NULL
PBMCs	NULL
from	NULL
GC-insensitive	NULL
patients	NULL
showing	NULL
(	NULL
e	NULL
)	NULL
immunoglobulin	NULL
isotype	NULL
control	NULL
for	NULL
GCR	NULL
-B	NULL
and	NULL
(	NULL
f	NULL
)	NULL
competitive	NULL
inhibition	NULL
of	NULL
GCR	NULL
-B	NULL
immunoreactivity	NULL
using	NULL
preabsorption	NULL
of	NULL
the	NULL
antibody	NULL
with	NULL
the	NULL
GCR	NULL
-B	NULL
peptide	NULL
.	NULL

1570	NULL
Glucocorticoid	NULL
Receptor	NULL
B	NULL
in	NULL
Glucorticoid-insensitive	NULL
Asthma	NULL
25-	NULL
o	NULL
--	NULL
0.001	NULL
--	NULL
--	NULL
--	NULL
r	NULL
--	NULL
P	NULL
<	NULL
0.001	NULL
=	NULL
--	NULL
%	NULL
GCR	NULL
B+	NULL
,	NULL
cee	NULL
Cells	NULL
0	NULL
og	NULL
U	NULL
154	NULL
U	NULL
U	NULL
104	NULL
t	NULL
8	NULL
$	NULL
54	NULL
e	NULL
go	NULL
0	NULL
T-	NULL
r	NULL
t	NULL
GC-insensitive	NULL
-	NULL
GC-sensitive	NULL
Normals	NULL
Asthma	NULL
Asthma	NULL
Figure	NULL
7	NULL
.	NULL

Percent	NULL
of	NULL
GCR-B*	NULL
cells	NULL
in	NULL
freshly	NULL
isolated	NULL
PBMCs	NULL
from	NULL
GC	NULL
-	NULL
insensitive	NULL
asthmatics	NULL
versus	NULL
GC	NULL
-sensitive	NULL
asthmatics	NULL
and	NULL
control	NULL
subjects	NULL
.	NULL

PBMCs	NULL
were	NULL
processed	NULL
and	NULL
stained	NULL
for	NULL
GCR	NULL
-B	NULL
immunoreactivity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Cells	NULL
positive	NULL
for	NULL
GCR	NULL
-B	NULL
were	NULL
scored	NULL
in	NULL
each	NULL
preparation	NULL
,	NULL
by	NULL
a	NULL
blinded	NULL
assessor	NULL
,	NULL
by	NULL
counting	NULL
1,000	NULL
cells	NULL
and	NULL
expressing	NULL
them	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
total	NULL
cell	NULL
population	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
could	NULL
account	NULL
for	NULL
GC-insensitive	NULL
asthma	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
PBMCs	NULL
cytospun	NULL
from	NULL
seven	NULL
GC-insensitive	NULL
asthmatics	NULL
,	NULL
six	NULL
GC-sensitive	NULL
asthmatics	NULL
,	NULL
and	NULL
seven	NULL
normal	NULL
subjects	NULL
were	NULL
stained	NULL
by	NULL
immunohistochemistry	NULL
technique	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
.	NULL

Positive	NULL
staining	NULL
for	NULL
GCR-B	NULL
was	NULL
observed	NULL
on	NULL
all	NULL
samples	NULL
stained	NULL
with	NULL
anti-GCR	NULL
-B	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
a-d	NULL
)	NULL
,	NULL
but	NULL
not	NULL
the	NULL
immunoglobulin	NULL
isotype	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
&	NULL
)	NULL
.	NULL

This	NULL
staining	NULL
was	NULL
blocked	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
purified	NULL
GCR	NULL
-B	NULL
immunizing	NULL
peptide	NULL
indicating	NULL
that	NULL
the	NULL
staining	NULL
was	NULL
specific	NULL
for	NULL
GCR	NULL
-B	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
f	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
GC-	NULL
insensitive	NULL
asthma	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
significantly	NULL
higher	NULL
percentage	NULL
of	NULL
GCR	NULL
-B*	NULL
cells	NULL
(	NULL
mean	NULL
+	NULL
SEM	NULL
=	NULL
20	NULL
+	NULL
0.8	NULL
%	NULL
;	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
than	NULL
GC	NULL
-sensitive	NULL
asthmatics	NULL
(	NULL
9	NULL
+	NULL
1	NULL
%	NULL
)	NULL
or	NULL
normal	NULL
controls	NULL
(	NULL
6	NULL
+	NULL
1	NULL
%	NULL
)	NULL
.	NULL

This	NULL
abnormal	NULL
GCR-B	NULL
expression	NULL
in	NULL
GC-insensitive	NULL
PBMCs	NULL
decreased	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
toward	NULL
normal	NULL
after	NULL
48	NULL
h	NULL
in	NULL
culture	NULL
media	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
incubation	NULL
with	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
sustained	NULL
this	NULL
abnormality	NULL
.	NULL

Furthermore	NULL
,	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
induced	NULL
significantly	NULL
greater	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
GCR	NULL
-B	NULL
expression	NULL
in	NULL
normal	NULL
PBMCs	NULL
as	NULL
compared	NULL
to	NULL
culture	NULL
medium	NULL
alone	NULL
or	NULL
baseline	NULL
values	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Discussion	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
patients	NULL
with	NULL
GC	NULL
-	NULL
insensitive	NULL
asthma	NULL
have	NULL
alterations	NULL
in	NULL
PBMC	NULL
GCR	NULL
ligand	NULL
and	NULL
DN	NULL
A	NULL
binding	NULL
affinity	NULL
.	NULL

These	NULL
GCR	NULL
binding	NULL
abnormalities	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
result	NULL
of	NULL
increased	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
,	NULL
a	NULL
molecule	NULL
which	NULL
we	NULL
have	NULL
demonstrated	NULL
to	NULL
inhibit	NULL
the	NULL
action	NULL
of	NULL
GCs	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
when	NULL
its	NULL
plasmid	NULL
is	NULL
transfected	NULL
into	NULL
COS-7	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
this	NULL
set	NULL
of	NULL
studies	NULL
,	NULL
we	NULL
found	NULL
that	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
was	NULL
cytokine	NULL
inducible	NULL
in	NULL
PBMCs	NULL
from	NULL
normal	NULL
subjects	NULL
,	NULL
and	NULL
reversed	NULL
to	NULL
normal	NULL
levels	NULL
in	NULL
GC-	NULL
insensitive	NULL
cells	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cytokines	NULL
.	NULL

Since	NULL
IL-2	NULL
and	NULL
IL-4	NULL
are	NULL
T	NULL
cell	NULL
growth	NULL
factors	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
preincubation	NULL
with	NULL
these	NULL
cytokines	NULL
could	NULL
result	NULL
in	NULL
a	NULL
selective	NULL
expansion	NULL
of	NULL
GC-insensitive	NULL
cells	NULL
has	NULL
been	NULL
previously	NULL
considered	NULL
(	NULL
7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
appears	NULL
to	NULL
be	NULL
un-	NULL
1572	NULL
MB	NULL
Normals	NULL
[	NULL
-	NULL
]	NULL
GC-insensitive	NULL
25	NULL
Asthma	NULL
%	NULL
GCR	NULL
13+	NULL
m-	NULL
P	NULL
<	NULL
0.001	NULL
--	NULL
-	NULL
P	NULL
<	NULL
0.001	NULL
--	NULL
Cells	NULL
204	NULL
e	NULL
--	NULL
P0.001	NULL
--	NULL
157	NULL
107	NULL
54	NULL
o	NULL
Time	NULL
of	NULL
incubation	NULL
(	NULL
hr	NULL
)	NULL
:	NULL
0	NULL
48	NULL
48	NULL
Treatment	NULL
:	NULL
0	NULL
Medium	NULL
Medium	NULL
+	NULL
1L2,4	NULL
Figure	NULL
8	NULL
.	NULL

Effect	NULL
of	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
on	NULL
percent	NULL
GCR	NULL
-B	NULL
immunoreactive	NULL
cells	NULL
in	NULL
PBMCs	NULL
from	NULL
normal	NULL
subjects	NULL
and	NULL
insensitive	NULL
asthmatics	NULL
.	NULL

PBMC	NULL
from	NULL
four	NULL
normal	NULL
donors	NULL
and	NULL
three	NULL
GC-insensitive	NULL
asthma	NULL
patients	NULL
were	NULL
analyzed	NULL
for	NULL
GCR	NULL
-	NULL
immunoreactivity	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

PBMCs	NULL
were	NULL
analyzed	NULL
for	NULL
GCR	NULL
-B	NULL
immunoreactivity	NULL
,	NULL
freshly	NULL
isolated	NULL
(	NULL
time	NULL
0	NULL
)	NULL
and	NULL
after	NULL
incubation	NULL
in	NULL
culture	NULL
medium	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
for	NULL
48	NULL
h.	NULL
likely	NULL
since	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
did	NULL
not	NULL
induce	NULL
lymphocyte	NULL
proliferation	NULL
,	NULL
nor	NULL
was	NULL
there	NULL
any	NULL
change	NULL
in	NULL
the	NULL
proportion	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
cells	NULL
over	NULL
this	NULL
48-h	NULL
time	NULL
period	NULL
.	NULL

Furthermore	NULL
,	NULL
incubation	NULL
with	NULL
IL-2	NULL
alone	NULL
or	NULL
IL-4	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
GCR	NULL
binding	NULL
.	NULL

Unpublished	NULL
observations	NULL
from	NULL
our	NULL
laboratory	NULL
also	NULL
indicate	NULL
that	NULL
GCR	NULL
alterations	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
begins	NULL
1	NULL
h	NULL
after	NULL
their	NULL
addition	NULL
to	NULL
PBMCs	NULL
,	NULL
supporting	NULL
the	NULL
concept	NULL
that	NULL
these	NULL
cytokines	NULL
are	NULL
not	NULL
simply	NULL
acting	NULL
as	NULL
T	NULL
cell	NULL
growth	NULL
factors	NULL
in	NULL
our	NULL
cell	NULL
culture	NULL
system	NULL
(	NULL
Leung	NULL
,	NULL
D.Y.M	NULL
.	NULL

,	NULL
and	NULL
S.J	NULL
.	NULL

Szefler	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
is	NULL
currently	NULL
unknown	NULL
.	NULL

GCR-a	NULL
«	NULL
and	NULL
GCR-B	NULL
are	NULL
generated	NULL
through	NULL
differential	NULL
splicing	NULL
of	NULL
the	NULL
same	NULL
GCR	NULL
pre-mRNA	NULL
transcript	NULL
(	NULL
13	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Changes	NULL
in	NULL
GCR	NULL
-	NULL
«	NULL
and	NULL
GCR	NULL
-B	NULL
levels	NULL
could	NULL
be	NULL
due	NULL
to	NULL
either	NULL
differences	NULL
in	NULL
the	NULL
rates	NULL
of	NULL
alternative	NULL
splicing	NULL
,	NULL
or	NULL
in	NULL
the	NULL
rates	NULL
of	NULL
RNA	NULL
or	NULL
protein	NULL
degradation	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
delineate	NULL
the	NULL
role	NULL
of	NULL
these	NULL
mechanisms	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
GC	NULL
insensitivity	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
report	NULL
demonstrating	NULL
that	NULL
cytokine-induced	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
may	NULL
be	NULL
directly	NULL
involved	NULL
in	NULL
the	NULL
development	NULL
of	NULL
GC-insensitivity	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
asthma	NULL
.	NULL

These	NULL
observations	NULL
have	NULL
important	NULL
implications	NULL
as	NULL
the	NULL
pathogenesis	NULL
of	NULL
other	NULL
clinical	NULL
conditions	NULL
associated	NULL
with	NULL
inflammation-induced	NULL
GC	NULL
insensitivity	NULL
may	NULL
also	NULL
involve	NULL
similar	NULL
mechanisms	NULL
.	NULL

During	NULL
the	NULL
past	NULL
three	NULL
decades	NULL
there	NULL
has	NULL
been	NULL
a	NULL
progressive	NULL
increase	NULL
in	NULL
morbidity	NULL
and	NULL
mortality	NULL
due	NULL
to	NULL
chronic	NULL
asthma	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
asthma	NULL
severity	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
changes	NULL
in	NULL
our	NULL
environment	NULL
,	NULL
particularly	NULL
with	NULL
regard	NULL
to	NULL
allergen	NULL
exposure	NULL
and	NULL
air	NULL
pollu-tion	NULL
,	NULL
both	NULL
of	NULL
which	NULL
stimulate	NULL
airway	NULL
inflammation	NULL
in	NULL
asthma	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Recent	NULL
epidemiologic	NULL
data	NULL
also	NULL
indicate	NULL
that	NULL
early	NULL
treatment	NULL
with	NULL
inhaled	NULL
GCs	NULL
to	NULL
gain	NULL
control	NULL
of	NULL
immune	NULL
activation	NULL
and	NULL
inflammation	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
success	NULL
ful	NULL
response	NULL
to	NULL
GCs	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Our	NULL
current	NULL
observation	NULL
that	NULL
immune	NULL
activation	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
GCR	NULL
-B	NULL
and	NULL
thereby	NULL
reduces	NULL
functional	NULL
responses	NULL
to	NULL
GCs	NULL
is	NULL
consistent	NULL
Glucocorticoid	NULL
Receptor	NULL
B	NULL
in	NULL
Glucorticoid-insensitive	NULL
Asthma	NULL
with	NULL
the	NULL
concept	NULL
that	NULL
inflammation	NULL
dampens	NULL
responses	NULL
to	NULL
endogenous	NULL
and	NULL
exogenous	NULL
GCs	NULL
.	NULL

Patients	NULL
with	NULL
GC-insensitive	NULL
asthma	NULL
have	NULL
a	NULL
tissue-specific	NULL
GC	NULL
insensitivity	NULL
and	NULL
are	NULL
therefore	NULL
often	NULL
subjected	NULL
to	NULL
continued	NULL
high	NULL
dose	NULL
treatment	NULL
with	NULL
GCs	NULL
,	NULL
despite	NULL
the	NULL
onset	NULL
of	NULL
serious	NULL
adverse	NULL
GC	NULL
effects	NULL
and	NULL
poor	NULL
clinical	NULL
response	NULL
to	NULL
GC	NULL
therapy	NULL
.	NULL

The	NULL
current	NULL
study	NULL
provides	NULL
a	NULL
novel	NULL
marker	NULL
to	NULL
identify	NULL
patients	NULL
with	NULL
GC	NULL
insensitivity	NULL
who	NULL
require	NULL
alternative	NULL
forms	NULL
of	NULL
antiinflammatory	NULL
and	NULL
immunomodulatory	NULL
therapy	NULL
.	NULL

An	NULL
understanding	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
GCs	NULL
fail	NULL
to	NULL
resolve	NULL
inflammation	NULL
in	NULL
asthma	NULL
will	NULL
provide	NULL
important	NULL
insights	NULL
into	NULL
the	NULL
pathogenesis	NULL
of	NULL
asthma	NULL
,	NULL
especially	NULL
as	NULL
it	NULL
relates	NULL
to	NULL
progressive	NULL
deterioration	NULL
,	NULL
and	NULL
should	NULL
result	NULL
in	NULL
the	NULL
rational	NULL
design	NULL
of	NULL
innovative	NULL
treatment	NULL
approaches	NULL
.	NULL

We	NULL
thank	NULL
Maureen	NULL
Plourd-	NULL
Sandoval	NULL
for	NULL
assistance	NULL
in	NULL
preparing	NULL
this	NULL
manuscript	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Lillester	NULL
A.	NULL
Colton	NULL
and	NULL
Amy	NULL
Fehringer	NULL
for	NULL
their	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Public	NULL
Health	NULL
Services	NULL
Research	NULL
grants	NULL
HL36577	NULL
,	NULL
AR41256	NULL
,	NULL
and	NULL
HL37260	NULL
,	NULL
and	NULL
General	NULL
Clinical	NULL
Research	NULL
Center	NULL
grant	NULL
5	NULL
MO1	NULL
RR	NULL
00051	NULL
from	NULL
the	NULL
Division	NULL
of	NULL
Research	NULL
Resources	NULL
,	NULL
the	NULL
University	NULL
of	NULL
Colorado	NULL
Cancer	NULL
Center	NULL
,	NULL
an	NULL
American	NULL
Lung	NULL
Association	NULL
Asthma	NULL
Research	NULL
Center	NULL
Grant	NULL
,	NULL
Medical	NULL
Research	NULL
Council	NULL
Canada	NULL
,	NULL
and	NULL
Inspiraplex	NULL
.	NULL

Address	NULL
Correspondence	NULL
to	NULL
Dr.	NULL
Donald	NULL
Y.M	NULL
.	NULL

Leung	NULL
,	NULL
National	NULL
Jewish	NULL
Medical	NULL
and	NULL
Research	NULL
Center	NULL
,	NULL
1400	NULL
Jackson	NULL
St.	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
80206	NULL
.	NULL

Phone	NULL
:	NULL
303-398-1379	NULL
;	NULL
FAX	NULL
:	NULL
303-270-2182	NULL
;	NULL
E-mail	NULL
:	NULL
leungd	NULL
@	NULL
nje.org	NULL
Received	NULL
for	NULL
publication	NULL
28	NULL
May	NULL
1997	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
20	NULL
August	NULL
1997	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Szefler	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
and	NULL
D.Y.M	NULL
.	NULL

Leung	NULL
.	NULL

1995	NULL
.	NULL

Severe	NULL
Asthma	NULL
:	NULL
Pathogenesis	NULL
and	NULL
Clinical	NULL
Management	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

557	NULL
pp	NULL
.	NULL

2	NULL
.	NULL

Corrigan	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
P.H	NULL
.	NULL

Brown	NULL
,	NULL
N.C.	NULL
Barnes	NULL
,	NULL
S.J	NULL
.	NULL

Szefler	NULL
,	NULL
J.-J	NULL
.	NULL

Tsai	NULL
,	NULL
A.J	NULL
.	NULL

Frew	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Kay	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
resis	NULL
tance	NULL
in	NULL
chronic	NULL
asthma	NULL
:	NULL
glucocorticoid	NULL
pharmacokinetics	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
characteristics	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cell	NULL
proliferation	NULL
by	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

144:1016-1025	NULL
.	NULL

3	NULL
.	NULL

Alvarez	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Surs	NULL
,	NULL
D.Y.M	NULL
.	NULL

Leung	NULL
,	NULL
D.	NULL
Iklé	NULL
,	NULL
EW	NULL
.	NULL

Gelfand	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Szefler	NULL
.	NULL

1992	NULL
.	NULL

Steroid-resistant	NULL
asthma	NULL
:	NULL
immunologic	NULL
and	NULL
pharmacologic	NULL
features	NULL
J	NULL
Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

89	NULL
:	NULL
714-721	NULL
.	NULL

4	NULL
.	NULL

Corrigan	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
P.H	NULL
.	NULL

Brown	NULL
,	NULL
N.C.	NULL
Barnes	NULL
,	NULL
J.-J	NULL
.	NULL

Tsai	NULL
,	NULL
A.J	NULL
.	NULL

Frew	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Kay	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
resistance	NULL
in	NULL
chronic	NULL
asthma	NULL
:	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocyte	NULL
activation	NULL
and	NULL
comparison	NULL
of	NULL
the	NULL
T	NULL
lymphocyte	NULL
inhibitory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

144:1026-1032	NULL
.	NULL

5	NULL
.	NULL

Bodwell	NULL
,	NULL
J.	NULL
,	NULL
J.-M.	NULL
Hu	NULL
,	NULL
and	NULL
A.	NULL
Munck	NULL
.	NULL

1996	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
:	NULL
ATP	NULL
and	NULL
cell	NULL
cycle	NULL
dependence	NULL
,	NULL
phosphorylation	NULL
and	NULL
hormone	NULL
resistance	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
Respir	NULL
Cnt	NULL
.	NULL

Care	NULL
Med	NULL
.	NULL

141	NULL
:	NULL
S2-S6	NULL
.	NULL

6	NULL
.	NULL

Sher	NULL
,	NULL
ER	NULL
.	NULL

,	NULL
D.Y.M	NULL
.	NULL

Leung	NULL
,	NULL
W.	NULL
Surs	NULL
,	NULL
J.C.	NULL
Kam	NULL
,	NULL
G.	NULL
Zieg	NULL
,	NULL
AK	NULL
.	NULL

Kamada	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Szefler	NULL
.	NULL

1994	NULL
.	NULL

Steroid-resistant	NULL
asthma	NULL
.	NULL

Cellular	NULL
mechanisms	NULL
contributing	NULL
to	NULL
inadequate	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

J	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

93:33-39	NULL
.	NULL

7	NULL
.	NULL

Kam	NULL
,	NULL
J.	NULL
,	NULL
S.J	NULL
.	NULL

Szefler	NULL
,	NULL
W.	NULL
Surs	NULL
,	NULL
E.	NULL
Sher	NULL
,	NULL
and	NULL
D.Y.M	NULL
.	NULL

Leung	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
combined	NULL
effects	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
alter	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

151	NULL
:	NULL
3460-3466	NULL
.	NULL

8	NULL
.	NULL

Leung	NULL
,	NULL
D.Y.M	NULL
.	NULL

,	NULL
R	NULL
.J	NULL
.	NULL

Martin	NULL
,	NULL
S.J	NULL
.	NULL

Szefler	NULL
,	NULL
E.R	NULL
.	NULL

Sher	NULL
,	NULL
S.	NULL
Ying	NULL
,	NULL
A.B	NULL
.	NULL

Kay	NULL
,	NULL
and	NULL
Q.	NULL
Hamid	NULL
.	NULL

1995	NULL
.	NULL

Dysregulation	NULL
of	NULL
interleukin	NULL
4	NULL
,	NULL
interleukin	NULL
5	NULL
,	NULL
and	NULL
interferon	NULL
y	NULL
gene	NULL
expression	NULL
in	NULL
steroid-resistant	NULL
asthma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:33-40	NULL
.	NULL

9	NULL
.	NULL

Adcock	NULL
,	NULL
I.	NULL
,	NULL
S.	NULL
Lane	NULL
,	NULL
C.	NULL
Brown	NULL
,	NULL
M.	NULL
Peters	NULL
,	NULL
T.	NULL
Lee	NULL
,	NULL
and	NULL
P.	NULL
1573	NULL
_	NULL
Leung	NULL
et	NULL
al	NULL
.	NULL

Barnes	NULL
.	NULL

1995	NULL
.	NULL

Differences	NULL
in	NULL
binding	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
to	NULL
DN	NULL
A	NULL
in	NULL
steroid	NULL
resistant	NULL
asthma	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

154:3500-3505	NULL
.	NULL

10	NULL
.	NULL

American	NULL
Thoracic	NULL
Society	NULL
.	NULL

1987	NULL
.	NULL

Standards	NULL
for	NULL
the	NULL
diagnosis	NULL
and	NULL
care	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
obstructive	NULL
pulmonary	NULL
dis	NULL
ease	NULL
(	NULL
COPD	NULL
)	NULL
and	NULL
asthma	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
Dis	NULL
.	NULL

136:225-244	NULL
.	NULL

11	NULL
.	NULL

Wheat	NULL
,	NULL
W.	NULL
,	NULL
W.	NULL
Roesler	NULL
,	NULL
and	NULL
D.	NULL
Klemm	NULL
.	NULL

1994	NULL
.	NULL

Simian	NULL
virus	NULL
40	NULL
small	NULL
tumor	NULL
antigen	NULL
inhibits	NULL
dephosphorylation	NULL
of	NULL
protein	NULL
kinase	NULL
A-phosphorylated	NULL
CREB	NULL
and	NULL
regulates	NULL
CREB	NULL
tran-scriptional	NULL
stimulation	NULL
.	NULL

Mol	NULL
.	NULL

Céll	NULL
.	NULL

Biol	NULL
.	NULL

14:5881-5890	NULL
.	NULL

12	NULL
.	NULL

Bokar	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
W.J	NULL
.	NULL

Roesler	NULL
,	NULL
G.R	NULL
.	NULL

Vandenbark	NULL
,	NULL
J.M	NULL
.	NULL

Kactzel	NULL
,	NULL
R.W	NULL
.	NULL

Hanson	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

Nilson	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
cAMP	NULL
responsive	NULL
elements	NULL
from	NULL
the	NULL
genes	NULL
for	NULL
the	NULL
-subunit	NULL
of	NULL
glycoprotein	NULL
hormones	NULL
and	NULL
phosphoenolpyruvate	NULL
carbox-ykinase	NULL
(	NULL
GTP	NULL
)	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:19740-19747	NULL
.	NULL

13.	NULL
de	NULL
Castro	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Elliot	NULL
,	NULL
T.	NULL
Kino	NULL
,	NULL
C.	NULL
Bamberger	NULL
,	NULL
M.	NULL
Karl	NULL
,	NULL
E.	NULL
Webster	NULL
,	NULL
and	NULL
G.P	NULL
.	NULL

Chrousos	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
non-ligand	NULL
binding	NULL
beta-isoform	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
hGR	NULL
beta	NULL
)	NULL
:	NULL
tissue	NULL
levels	NULL
,	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
and	NULL
potential	NULL
physi-ologic	NULL
role	NULL
.	NULL

Mol	NULL
.	NULL

Med	NULL
.	NULL

2:597-607	NULL
.	NULL

14	NULL
.	NULL

Giaid	NULL
,	NULL
A.	NULL
,	NULL
R.	NULL
Michel	NULL
,	NULL
D.	NULL
Stewart	NULL
,	NULL
M.	NULL
Sheppard	NULL
,	NULL
B.	NULL
Corrin	NULL
,	NULL
and	NULL
Q.	NULL
Hamid	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
of	NULL
endothelin-1	NULL
in	NULL
lungs	NULL
of	NULL
patients	NULL
with	NULL
cryptogenic	NULL
fibrosing	NULL
alveolitis	NULL
Lanet	NULL
341	NULL
:	NULL
1550-1554	NULL
.	NULL

15	NULL
.	NULL

Hollenberg	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
C.	NULL
Weinberger	NULL
,	NULL
E.S	NULL
.	NULL

Ong	NULL
,	NULL
G.	NULL
Cerelli	NULL
,	NULL
A.	NULL
Oro	NULL
,	NULL
R.	NULL
Lebo	NULL
,	NULL
E.B	NULL
.	NULL

Thompson	NULL
,	NULL
M.G	NULL
.	NULL

Rosenfeld	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Evans	NULL
.	NULL

1985	NULL
.	NULL

Primary	NULL
structure	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
functional	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
cDNA	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

318	NULL
:	NULL
635-641	NULL
.	NULL

16	NULL
.	NULL

Bamberger	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
A.M.	NULL
Bamberger	NULL
,	NULL
M.	NULL
de	NULL
Castro	NULL
,	NULL
and	NULL
G.P	NULL
.	NULL

Chrousos	NULL
.	NULL

1995	NULL
.	NULL

Glucocorticoid	NULL
receptor	NULL
beta	NULL
,	NULL
a	NULL
potential	NULL
endogenous	NULL
inhibitor	NULL
of	NULL
glucocorticoid	NULL
action	NULL
in	NULL
humans	NULL
.	NULL

J	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

95:6:2435-2441	NULL
.	NULL

17	NULL
.	NULL

Oakley	NULL
,	NULL
R	NULL
.H	NULL
.	NULL

,	NULL
M.	NULL
Sar	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

Cidlowski	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
beta	NULL
isoform	NULL
.	NULL

Expression	NULL
,	NULL
biochemical	NULL
properties	NULL
,	NULL
and	NULL
putative	NULL
function	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

271	NULL
:	NULL
9550-9559.	NULL
visits	NULL
for	NULL
asthma	NULL
in	NULL
Seattle	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
Dis	NULL
.	NULL

147:826-831	NULL
.	NULL

18	NULL
.	NULL

Sears	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
G.P	NULL
.	NULL

Herbison	NULL
,	NULL
M.D	NULL
.	NULL

Holdaway	NULL
,	NULL
C.J	NULL
.	NULL

Hewitt	NULL
,	NULL
20	NULL
.	NULL

Haahtela	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Jarvinen	NULL
,	NULL
and	NULL
T.	NULL
Kava	NULL
.	NULL

1994	NULL
.	NULL

Effects	NULL
of	NULL
re	NULL
E.M.	NULL
Flannery	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Silva	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
relative	NULL
risk	NULL
of	NULL
sen-	NULL
ducing	NULL
or	NULL
discontinuing	NULL
inhaled	NULL
budesonide	NULL
in	NULL
patients	NULL
with	NULL
sitivity	NULL
to	NULL
grass	NULL
pollen	NULL
,	NULL
house	NULL
dust	NULL
mite	NULL
and	NULL
cat	NULL
dander	NULL
in	NULL
the	NULL
mild	NULL
asthma	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

331:700-705.	NULL
development	NULL
of	NULL
childhood	NULL
asthma	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Allegy	NULL
.	NULL

19	NULL
:	NULL
21	NULL
.	NULL

Agertoft	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
S.	NULL
Pedersen	NULL
.	NULL

1994	NULL
.	NULL

Effects	NULL
of	NULL
long-term	NULL
419-424.	NULL
treatment	NULL
with	NULL
an	NULL
inhaled	NULL
corticosteroid	NULL
on	NULL
growth	NULL
and	NULL
pul-19	NULL
.	NULL

Schwartz	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Slater	NULL
,	NULL
T.	NULL
Larson	NULL
,	NULL
W.	NULL
Pierson	NULL
,	NULL
and	NULL
J.	NULL
Koenig	NULL
.	NULL

monary	NULL
function	NULL
in	NULL
asthmatic	NULL
children	NULL
.	NULL

Respir	NULL
.	NULL

Med	NULL
.	NULL

88:373-381	NULL
.	NULL

1993	NULL
.	NULL

Particulate	NULL
air	NULL
pollution	NULL
and	NULL
hospital	NULL
emergency	NULL
room	NULL
1574	NULL
_	NULL
Glucocorticoid	NULL
Receptor	NULL
B	NULL
in	NULL
Glucorticoid-insensitive	NULL
Asthma	NULL

